
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Market Size (2025) | USD 0.73 Billion |
Market Size (2030) | USD 1.30 Billion |
CAGR (2025 - 2030) | 12.18 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Platelet-Rich Plasma (PRP) Market Analysis
The Global Platelet Rich Plasma Market size is estimated at USD 0.73 billion in 2025, and is expected to reach USD 1.30 billion by 2030, at a CAGR of 12.18% during the forecast period (2025-2030).
The key factors augmenting the platelet-rich plasma (PRP) market growth include the rising incidence of sports injuries, increasing cosmetic and surgical procedures, and the growing use of platelet-rich plasma in various therapeutic areas. The increasing burden of chronic diseases such as cardiovascular diseases among the population raises the demand for treatment through surgical intervention involving the use of PRP therapy. For instance, the use of platelet rich plasma (PRP) decreases the incidence and costs of wound complications and wound healing following cardiac and general surgery. Hence, the market growth of platelet rich plasma is anticipated to augment over the forecast period. For instance, as per the data from the Centers for Disease Control and Prevention (CDC) updated in May 2023, it was found that around 805,000 people in the United States have a heart attack every year. The growing number of heart attacks is leading to many surgical procedures, such as angioplasty, which is likely to augment the market growth. Additionally, as per the World Health Organization 2023 reports, the incidences of traumatic injuries, cancers, and cardiovascular disease continue to rise, and the impact of surgical intervention on public health systems will continue to grow globally, which is expected to enhance the demand of advanced PRP therapies around the globe.
The emergence of advanced PRP treatments and their utilization in various therapeutic fields have also helped the PRP market expand significantly. For instance, in December 2023, Hairline International Hair and Skin Clinic launched an advanced hair regeneration therapy called Sonicated PRP for hair loss, based on groundbreaking research utilizing platelet-rich plasma (PRP). The cutting-edge treatment aims to revolutionize hair follicle activation and regeneration. Similarly, in June 2023, Isto Biologics, a leader in orthobiologic regeneration technologies, launched Precise, a brand-new, state-of-the-art technology that delivers a final PRP product with precision cellular fractions upon concentration. Hence, owing to such advancements and PRP treatment, the launch of PRP therapies is expected to support the market growth positively and increase its adoption in various medical fields.
However, industry analysis shows that PRP treatments can be costly, especially in cases where multiple sessions are required. The expenses associated with the procedure — such as blood collection, processing, and preparation of the plasma — limit accessibility for some patients. In addition, the regulatory environment surrounding PRP treatments is unclear in many countries, making it difficult for medical practitioners to understand the legal framework which is likely to restraint the market growth.
Platelet Rich Plasma Market Insights and Trends
Pure PRP Segment is Expected to Have Major Share in the Market Over the Forecast Period
By type, the Pure PRP segment is estimated to have a platelet rich plasma market size of USD 0.31 billion in 2024, which is expected to reach USD 0.55 billion by 2029 with a CAGR of 12.03% over the forecast period.
Pure platelet-rich plasma is a specific type of PRP treatment focused on maximizing the concentration of platelets and growth factors in blood plasma. Pure PRP is a platelet-rich plasma (PRP) preparation that contains high concentrations of platelet growth factors and fewer red blood cells. They are commonly used in orthopedics, dermatology, dentistry, and aesthetics to promote tissue healing process and regeneration.
Positive clinical outcomes and patient satisfaction have played a significant role in driving the demand for pure PRP. For instance, the data published by the PRP Labs in September 2023 stated that research conducted by BSR and the Brazilian team on Pure PRP revealed that products like EmCytePure PRP showed a higher platelet recovery rate than other platelet kits. A higher platelet recovery rate can enhance collagen production, improve skin tone and texture, promote hair growth, and reduce the appearance of fine lines and wrinkles. Hence, owing to the increase in advantages offered by the pure PRP, the demand for the same is likely to rise, leading to pure PRP segment growth over the forecast period.
Furthermore, the global population is aging, leading to an increased demand for anti-aging therapy, which drives the segment growth. Pure PRP has shown potential in addressing age-related orthopedic issues, such as joint pain and osteoarthritis, as well as for rejuvenating skin. The expanding aging population has fueled the demand for pure PRP treatments. According to data published in the Journal of Head & Face Medicine in June 2023, a cohort study showed that Pure PRP injections result in significant skin rejuvenation. Such supportive study results will raise the demand for pure PRP in cosmetic procedures, which will drive segment growth. Hence, owing to the effective treatment with pure PRP and the increasing global aging population which raises the demand for PRP, is believed to be contributing to the segment’s growth. However, the pure platelet rich plasma segment of the PRP industry faces several hurdles, including high treatment costs, inconsistent clinical outcomes, technological limitations, and a lack of robust regulatory frameworks.

The Hospital & Clinics Segment is Expected to Have a Largest Share of the Market Over the Forecast Period
By end user, the hospital & clinics segment is estimated to have the largest platelet rich plasma market share with a market size of USD 0.56 billion in 2024, which is expected to reach USD 0.98 billion by 2029 with a CAGR of 12.08% over the forecast period.
Hospitals are pivotal to the healthcare system, serving diverse functions that enhance the population's overall well-being. Equipped with specialized tools for blood sample processing, hospitals and clinics boast the infrastructure and expertise to administer platelet-rich plasma therapy. Their skilled professionals ensure procedures are conducted in sterile environments, prioritizing patient safety during both the preparation and administration of the therapy. The segment is driven by the increasing number of patient admissions for different diseases and disorders, such as orthopedic and neurological disorders, and the rising awareness about the use of platelet-rich plasma.
The platelet rich plasma market segmentation includes type, application, and end user. By type, the market is segmented into pure PRP, leukocyte-rich PRP, leukocyte-rich fibrin, and other types. By application, the market is segmented into orthopedics, cosmetic surgery and dermatology, neurology, cardiology, ophthalmology, and other applications. By end user, the market is segmented into hospitals and clinics, and research institutes. Understanding these segments is crucial for identifying market trends, growth opportunities, understanding market forecast and addressing the challenges within the industry, for market leaders as well as all players.
Asia-Pacific is Expected to Have a Fastest Growth Rate in the Market Over the Forecast Period
By geography, the Asia-Pacific (APAC) region is likely to hold the fastest platelet rich plasma industry growth rate with an estimated market size of USD 0.17 billion in 2024, expected to reach USD 0.31 billion by 2029 with a CAGR of 13.19% over the forecast period. The Asia-Pacific platelet rich plasma market is experiencing rapid growth , driven by several key factors such as rising healthcare investments, increasing awareness of aesthetic and regenerative medicine, and advancements in technology, which make it one of the most promising markets for PRP therapies globally. The growth is particularly noticeable in countries like China, India, Japan, South Korea, and Australia.
The rising prevalence of knee osteoarthritis cases and the growing number of knee replacements and hip replacement surgeries in the region are projected to boost platelet-rich plasma (PRP) market growth in APAC during the forecast period. For instance, according to the data published by the Australian Institute of Health and Welfare in January 2024, musculoskeletal conditions in Australia were responsible for 13% of the total burden of disease in 2023. Of this proportion, osteoarthritis contributed 20% of the disease burden. In addition, according to the same source, 53,500 knee replacements (210 per 100,000 population) and 35,500 hip replacements (140 per 100,000 population) surgeries were performed to treat osteoarthritis in Australia in 2021-2022. These surgeries use platelet-rich plasma injections to reduce joint pain, improve joint function, and even repair damage to the cartilage. Thus, the increasing prevalence of knee osteoarthritis cases drives the adoption of platelet-rich plasma, thereby influencing market growth in Asia Pacific region.
Moreover, the initiatives by different organizations to set up conferences and workshops promoting the use of platelet-rich plasma therapies are projected to drive market growth. For instance, in May 2023, the event organizer Mangus Group Ltd held an international conference on Dermatology and cosmetology in Tokyo, Japan. The conference discussed the positive results of plasma therapies from clinical studies for aging. Such conferences promoting the use of PRP for dermatology applications are expected to promote market growth in Japan. Thus, factors such as the rising prevalence of arthritis in Asia Pacific, and initiatives by different organizations to set up conferences and workshops promoting the use of platelet-rich plasma therapies are set to drive market growth during the forecast period.
By geography, the global platelet rich plasma market research is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Europe has a well-established PRP market, particularly in countries like Germany, the United Kingdom, and France. The demand for PRP in dermatology, orthopedics, and sports medicine is growing, though regulatory hurdles in certain countries can limit its growth.

Platelet Rich Plasma Industry Overview
The platelet-rich plasma market is highly competitive, with several players involved in the production of PRP products. The global market includes a mix of established medical device companies, specialized biotech firms, and regional players that offer a variety of PRP products targeting different medical fields such as orthopedic surgery, dermatology, aesthetics, and sports medicine.
Some of the key players currently dominating the market are Arthrex Inc., Isto Biologics, Vertical Spine LLC, DePuy Synthes, Dr. PRP USA LLC, EmCyte Corporation, Glofinn Oy, T-Biotechnology, Terumo BCT Inc., Zimmer Biomet, Harvest Technologies Corporation, ISTO Biologics. Companies focus on launching new products and getting approvals, which is likely to increase the availability of the products in the market.
For instance, in June 2023, Isto Biologics introduced Precise, the latest breakthrough in autologous therapies. Precise is an innovative and advanced technology that produces a highly concentrated platelet-rich plasma product with precise cellular fractions. The CellectFlex Technology of the Precise system enables customization of cell compositions during each spin, resulting in a unique range of offerings that were previously unavailable.
In addition, various players employ strategies like product innovation, geographic expansion, and M&A to maintain or grow their market share.
Platelet-Rich Plasma (PRP) Market Leaders
-
EmCyte Corporation
-
Zimmer Biomet
-
Johnson & Johnson (DePuy Synthes)
-
Arthrex Inc.
-
Terumo BCT Inc
- *Disclaimer: Major Players sorted in no particular order

Platelet-Rich Plasma (PRP) Market News
- September 2024: the United States FDA cleared the FG-001 Platelet Rich Plasma (PRP) Device which is designed to be used for the safe and rapid preparation of platelet rich plasma (PRP) from a small sample of blood at the patient’s point of care.
- August 2024: the United States FDA approved Illuminate PRP, designed for the swift and safe preparation of autologous platelet-rich plasma (PRP) from a minor peripheral blood sample, directly at the patient's point-of-care.
- April 2024: The United States FDA has approved the Thrombinator System for use with Arthrex PRP Systems. These include the Arthrex Angel concentrated Platelet Rich Plasma (cPRP) System, the Arthrex Double Syringe (ACP) System, and the Arthrex ACP Max Platelet-Rich Plasma (PRP) System. The Thrombinator System is engineered to prepare autologous serum from both anticoagulated and non-anticoagulated peripheral blood. It can also process platelet-poor plasma and platelet-rich plasma (PRP). This prepared serum is intended to be mixed with PRP and either autograft or allograft bone before being applied to a bony defect, enhancing the handling characteristics of the mixture.
- January 2024: Arthrex Demonstrated to the media the use of the ACP Max system for creating a highly concentrated platelet-rich plasma (PRP) with low neutrophil content.
Platelet-Rich Plasma (PRP) Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidences of Sports Injuries
- 4.2.2 Increasing Number of Cosmetic and Surgical Procedures
- 4.2.3 Growing Use of Platelet Rich Plasma in Various Therapeutic Areas
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Policies
- 4.3.2 High Prices of Plasma Therapy
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD billion)
-
5.1 By Type
- 5.1.1 Pure PRP
- 5.1.2 Leukocyte-Rich PRP
- 5.1.3 Leukocyte-Rich Fibrin
- 5.1.4 Other Types
-
5.2 By Application
- 5.2.1 Orthopedics
- 5.2.2 Cosmetic Surgery and Dermatology
- 5.2.3 Neurology
- 5.2.4 Cardiology
- 5.2.5 Ophthalmology
- 5.2.6 Other Applications
-
5.3 By End User
- 5.3.1 Hospitals & Clinics
- 5.3.2 Research Institutes
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Arthrex Inc.
- 6.1.2 Isto Biologics
- 6.1.3 Vertical Spine LLC
- 6.1.4 DePuy Synthes
- 6.1.5 Dr. PRP USA LLC
- 6.1.6 EmCyte Corporation
- 6.1.7 Glofinn Oy
- 6.1.8 T-Biotechnology
- 6.1.9 Terumo BCT Inc.
- 6.1.10 Zimmer Biomet
- 6.1.11 Harvest Technologies Corporation
- 6.1.12 ISTO Biologics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Platelet-Rich Plasma (PRP) Industry Segmentation
As per the report's scope, platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels (which contains at least seven growth factors). Platelet-rich plasma therapy employs injections of the patient's concentrated platelets to accelerate the healing of injured tendons, ligaments, muscles, and joints.
The platelet rich plasma market segmentation includes type, application, end user, and geography. By type, the market is segmented into pure PRP, leukocyte-rich PRP, leukocyte-rich fibrin, and other types. By application, the market is segmented into orthopedics, cosmetic surgery and dermatology, neurology, cardiology, ophthalmology, and other applications. By end user, the market is segmented into hospitals and clinics, and research institutes. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market value (in USD billion) for the above segments. By Type Pure PRP Leukocyte-Rich PRP Leukocyte-Rich Fibrin Other Types By Application Orthopedics Cosmetic Surgery and Dermatology Neurology Cardiology Ophthalmology Other Applications By End User Hospitals & Clinics Research Institutes By Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America
By Type | Pure PRP | ||
Leukocyte-Rich PRP | |||
Leukocyte-Rich Fibrin | |||
Other Types | |||
By Application | Orthopedics | ||
Cosmetic Surgery and Dermatology | |||
Neurology | |||
Cardiology | |||
Ophthalmology | |||
Other Applications | |||
By End User | Hospitals & Clinics | ||
Research Institutes | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Platelet-Rich Plasma (PRP) Market Research FAQs
What are the main factors driving the growth of PRP ?
The key factors driving the market's growth include the rising incidence of sports injuries, increasing cosmetic and surgical procedures, and the growing use of platelet-rich plasma in various therapeutic areas.
Who are the major players in the PRP market?
EmCyte Corporation, Zimmer Biomet, Johnson & Johnson (DePuy Synthes), Arthrex Inc. and Terumo BCT Inc. are the major players operating in the platelet rich plasma market.
What are the current and emerging trends in PRP ?
Current and emerging trends in the PRP market include the increasing use of PRP for non-invasive aesthetic treatments like hair restoration and facial rejuvenation, growing adoption in orthopedic and regenerative medicine, advancements in PRP preparation technologies, and expanding market access in emerging regions like Asia-Pacific.
How much is the blood plasma market worth?
Blood plasma market was valued at USD 0.73 Billion in 2025 and is projected to reach USD 1.30 Billion by 2030, growing at a CAGR of 12.18% from 2025 to 2030.